A four-microRNA classifier as a novel prognostic marker for tumor recurrence in stage II colon cancer

[1]  O. Dahl,et al.  Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer , 2017, Oncotarget.

[2]  You-cai Zhao,et al.  A BAP1 Mutation-specific MicroRNA Signature Predicts Clinical Outcomes in Clear Cell Renal Cell Carcinoma Patients with Wild-type BAP1 , 2017, Journal of Cancer.

[3]  X. Liu,et al.  Increasing expression of miR-5100 in non-small-cell lung cancer and correlation with prognosis. , 2017, European review for medical and pharmacological sciences.

[4]  A. Navarro,et al.  Identifying High-Risk Stage II Colon Cancer Patients: A Three-MicroRNA-Based Score as a Prognostic Biomarker. , 2016, Clinical colorectal cancer.

[5]  C. Sarkar,et al.  Clinicopathological characteristics, molecular subgrouping, and expression of miR-379/miR-656 cluster (C14MC) in adult medulloblastomas , 2016, Journal of Neuro-Oncology.

[6]  J. Jassem,et al.  Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer , 2016, Clinical & Experimental Metastasis.

[7]  D. Kamp,et al.  miR-5100 promotes tumor growth in lung cancer by targeting Rab6. , 2015, Cancer letters.

[8]  F. Sinicrope,et al.  Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer , 2015, Current Treatment Options in Oncology.

[9]  R. Salazar,et al.  Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Calin,et al.  Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs , 2015, Oncotarget.

[11]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[12]  T. Blondal,et al.  Redefining high-risk patients with stage II colon cancer by risk index and microRNA-21: results from a population-based cohort , 2014, British Journal of Cancer.

[13]  J. Jónasson,et al.  pT4 stage II and III colon cancers carry the worst prognosis in a nationwide survival analysis. Shepherd's local peritoneal involvement revisited , 2014, International journal of cancer.

[14]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[15]  R. Labianca,et al.  Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. , 2014 .

[16]  E. Bowman,et al.  High miR‐21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer , 2014, International journal of cancer.

[17]  W. Hohenberger,et al.  The rationale behind complete mesocolic excision (CME) and a central vascular ligation for colon cancer in open and laparoscopic surgery , 2014, International Journal of Colorectal Disease.

[18]  Jian Lu,et al.  Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. , 2013, The Lancet. Oncology.

[19]  D. Sargent,et al.  Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G. Eide,et al.  Outcome after Introduction of Complete Mesocolic Excision for Colon Cancer Is Similar for Open and Laparoscopic Surgical Treatments , 2013, Digestive Surgery.

[21]  D. Ichikawa,et al.  Comparison of prognostic compatibility between seventh AJCC/TNM of the esophagus and 14th JCGC staging systems in Siewert type II adenocarcinoma. , 2013, Anticancer research.

[22]  Arijit Mukhopadhyay,et al.  Genome-wide analysis reveals downregulation of miR-379/miR-656 cluster in human cancers , 2013, Biology Direct.

[23]  R. Lothe,et al.  Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  R. Labianca,et al.  Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. , 2012, Journal of the National Cancer Institute.

[25]  Greg Yothers,et al.  Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value , 2012, Clinical Cancer Research.

[26]  R. Aharonov,et al.  Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer. , 2012, International journal of oncology.

[27]  D. Kerr,et al.  Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Sebastian D. Mackowiak,et al.  miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades , 2011, Nucleic acids research.

[29]  Maureen A. Smith,et al.  Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  C. Boland,et al.  Colorectal Cancers with Microsatellite Instability Display Unique miRNA Profiles , 2011, Clinical Cancer Research.

[31]  D. Kerr,et al.  Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Robinson,et al.  A scaling normalization method for differential expression analysis of RNA-seq data , 2010, Genome Biology.

[33]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[34]  Sabine Tejpar,et al.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Goeman.  L1 Penalized Estimation in the Cox Proportional Hazards Model , 2009, Biometrical journal. Biometrische Zeitschrift.

[36]  R. Labianca,et al.  Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. Mukherjee,et al.  Adjuvant therapy for completely resected stage II colon cancer. , 2008, The Cochrane database of systematic reviews.

[38]  D. Kerr,et al.  Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study , 2007, The Lancet.

[39]  R. Gray,et al.  Randomised trials of HIV prevention , 2007, The Lancet.

[40]  D. Forman,et al.  Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology , 2007, Gut.

[41]  Eugene Berezikov,et al.  Approaches to microRNA discovery , 2006, Nature Genetics.

[42]  D. Rimm,et al.  X-Tile , 2004, Clinical Cancer Research.

[43]  M. Somerfield,et al.  American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  S. Cha,et al.  Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Daniel J Sargent,et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.

[46]  Daniel J Sargent,et al.  Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[48]  Ratkin Ga.  Adjuvant therapy for colon and rectal cancer. , 1997 .

[49]  A. Guermazi,et al.  Results from a Population-based Cohort Study Detect Early Onset and Progression of Articular Cartilage Degeneration : Ability of a Urine Assay of Type II Collagen Cleavage by Collagenases to , 2016 .

[50]  N. Petrelli,et al.  Predictive Biomarkers and Personalized Medicine MutationPro fi ling andMicrosatellite Instability in Stage II and III Colon Cancer : An Assessment of Their Prognostic and Oxaliplatin Predictive Value , 2012 .

[51]  A. Jaffe,et al.  Reduction of infarct size in patients with inferior infarction with intravenous glyceryl trinitrate. A randomised study. , 1983, British heart journal.

[52]  G. Ratkin.  Adjuvant therapy for colon and rectal cancer. , 1997, American family physician.

[53]  R. Tibshirani.  Regression Shrinkage and Selection via the Lasso , 1996 .